المؤلفون: Subramaniam K., Svenningsen L., Baekdal M., Kammerlander H., Walsh A., Boysen T., Bampton P., Radford-Smith G., Kjeldsen J., Andrews J.M., Vestergaard T., Moore G.T., Jensen N.M., Connor S.J., Wildt S., Wilson B., Ellard K., Christensen L.A., Bell S.J., Julsgaard M., Hvas C.L., Gearry R.B., Gibson P.R., Fallingborg J., Sparrow M.P., Bibby B.M., Connell W.R., Brown S.J., Kamm M.A., Lawrance I.C.

مصطلحات الفهرس: budesonide/pv [Special Situation for Pharmacovigilance], infliximab/cb [Drug Combination], infliximab/cm [Drug Comparison], infliximab/dt [Drug Therapy], infliximab/pv [Special Situation for Pharmacovigilance], mercaptopurine/cb [Drug Combination], mercaptopurine/dt [Drug Therapy], mercaptopurine/pv [Special Situation for Pharmacovigilance], mesalazine/pv [Special Situation for Pharmacovigilance], prednisolone/dt [Drug Therapy], prednisolone/pv [Special Situation for Pharmacovigilance], tumor necrosis factor antibody/cb [Drug Combination], tumor necrosis factor antibody/dt [Drug Therapy], tumor necrosis factor antibody/to [Drug Toxicity], tumor necrosis factor antibody/pv [Special Situation for Pharmacovigilance], mesalazine/dt [Drug Therapy], adult, adverse outcome, article, attitude to illness, Australia, cohort analysis, controlled study, Crohn disease/dt [Drug Therapy], Denmark, disease activity, female, fetus, gestational age, human, inflammatory bowel disease/dt [Drug Therapy], low birth weight, major clinical study, male, medical information, New Zealand, newborn, patient counseling, patient satisfaction, prediction, pregnancy outcome, pregnant woman, priority journal, prospective study, questionnaire, recurrence risk, risk assessment, third trimester pregnancy, treatment response, ulcerative colitis/dt [Drug Therapy], adalimumab/cb [Drug Combination], adalimumab/cm [Drug Comparison], adalimumab/dt [Drug Therapy], adalimumab/pv [Special Situation for Pharmacovigilance], allopurinol/cb [Drug Combination], allopurinol/dt [Drug Therapy], allopurinol/pv [Special Situation for Pharmacovigilance], budesonide/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29311
Inflammatory Bowel Diseases
Click here for full text options
LibKey Link

المؤلفون: Subramaniam K., Svenningsen L., Baekdal M., Kammerlander H., Walsh A., Boysen T., Bampton P., Radford-Smith G., Kjeldsen J., Andrews J.M., Vestergaard T., Moore G.T., Jensen N.M., Connor S.J., Wildt S., Wilson B., Ellard K., Christensen L.A., Bell S.J., Julsgaard M., Hvas C.L., Gearry R.B., Gibson P.R., Fallingborg J., Sparrow M.P., Bibby B.M., Connell W.R., Brown S.J., Kamm M.A., Lawrance I.C.

مصطلحات الفهرس: budesonide/pv [Special Situation for Pharmacovigilance], infliximab/cb [Drug Combination], infliximab/cm [Drug Comparison], infliximab/dt [Drug Therapy], infliximab/pv [Special Situation for Pharmacovigilance], mercaptopurine/cb [Drug Combination], mercaptopurine/dt [Drug Therapy], mercaptopurine/pv [Special Situation for Pharmacovigilance], mesalazine/pv [Special Situation for Pharmacovigilance], prednisolone/dt [Drug Therapy], prednisolone/pv [Special Situation for Pharmacovigilance], tumor necrosis factor antibody/cb [Drug Combination], tumor necrosis factor antibody/dt [Drug Therapy], tumor necrosis factor antibody/to [Drug Toxicity], tumor necrosis factor antibody/pv [Special Situation for Pharmacovigilance], mesalazine/dt [Drug Therapy], adult, adverse outcome, article, attitude to illness, Australia, cohort analysis, controlled study, Crohn disease/dt [Drug Therapy], Denmark, disease activity, female, fetus, gestational age, human, inflammatory bowel disease/dt [Drug Therapy], low birth weight, major clinical study, male, medical information, New Zealand, newborn, patient counseling, patient satisfaction, prediction, pregnancy outcome, pregnant woman, priority journal, prospective study, questionnaire, recurrence risk, risk assessment, third trimester pregnancy, treatment response, ulcerative colitis/dt [Drug Therapy], adalimumab/cb [Drug Combination], adalimumab/cm [Drug Comparison], adalimumab/dt [Drug Therapy], adalimumab/pv [Special Situation for Pharmacovigilance], allopurinol/cb [Drug Combination], allopurinol/dt [Drug Therapy], allopurinol/pv [Special Situation for Pharmacovigilance], budesonide/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29311
Inflammatory Bowel Diseases
LibKey Link